Published in FEBS Lett on June 19, 2003
RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev (2007) 3.13
ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int (2005) 1.83
Nanodrug delivery in reversing multidrug resistance in cancer cells. Front Pharmacol (2014) 1.05
Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology. J Control Release (2011) 1.01
RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells. J Cell Mol Med (2008) 0.90
Cell-penetrating, guanidinium-rich molecular transporters for overcoming efflux-mediated multidrug resistance. Mol Pharm (2014) 0.89
RNAi technology: a revolutionary tool for the colorectal cancer therapeutics. World J Gastroenterol (2006) 0.88
Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy. Expert Opin Drug Deliv (2008) 0.86
Gene therapy for gastric cancer: is it promising? World J Gastroenterol (2006) 0.86
Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study. Clin Orthop Relat Res (2013) 0.85
Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides. Nucleic Acids Res (2004) 0.85
Reversal of multi-drug resistance by pSUPER-shRNA-mdr1 in vivo and in vitro. World J Gastroenterol (2009) 0.83
Role of Caveolin-1 in Indomethacin-induced Death of Human Hepatoadenocarcinoma SK-Hep1 Cells. Korean J Physiol Pharmacol (2008) 0.82
Gene therapy in pancreatic cancer. World J Gastroenterol (2014) 0.81
Reversing multidrug resistance by RNA interference through the suppression of MDR1 gene in human hepatoma cells. World J Gastroenterol (2006) 0.81
Modulating drug resistance by targeting BCRP/ABCG2 using retrovirus-mediated RNA interference. PLoS One (2014) 0.80
The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy. BMC Cancer (2010) 0.79
VEGF T-1498C polymorphism, a predictive marker of differentiation of colorectal adenocarcinomas in Japanese. Int J Med Sci (2008) 0.79
Silencing the epidermal growth factor receptor gene with RNAi may be developed as a potential therapy for non small cell lung cancer. Genet Vaccines Ther (2005) 0.79
Bacterial delivery of RNAi effectors: transkingdom RNAi. J Vis Exp (2010) 0.78
Short hairpin RNA-mediated MDR1 gene silencing increases apoptosis of human ovarian cancer cell line A2780/Taxol. Chin J Cancer Res (2012) 0.75
New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids. Acta Naturae (2009) 0.75
Tackling breast cancer chemoresistance with nano-formulated siRNA. Gene Ther (2016) 0.75
Nano-based delivery of RNAi in cancer therapy. Mol Cancer (2017) 0.75
Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol (2003) 2.04
Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples. PLoS One (2009) 1.55
A prognostic gene expression index in ovarian cancer - validation across different independent data sets. J Pathol (2009) 1.55
Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer (2006) 1.53
Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res (2008) 1.29
Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol (2003) 1.23
Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Res (2006) 1.16
RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Biochem Biophys Res Commun (2006) 1.09
ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clin Cancer Res (2006) 1.08
Overexpression of cathepsin B in gastric cancer identified by proteome analysis. Proteomics (2005) 1.08
Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res (2005) 1.07
Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A. Int J Cancer (2003) 1.07
Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Arch (2005) 1.06
Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells. Int J Cancer (2005) 1.02
Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene (2005) 1.01
YB-1 relocates to the nucleus in adenovirus-infected cells and facilitates viral replication by inducing E2 gene expression through the E2 late promoter. J Biol Chem (2002) 1.01
Enhanced exposure of phosphatidylserine in human gastric carcinoma cells overexpressing the half-size ABC transporter BCRP (ABCG2). Biochem J (2003) 1.01
Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference. Cancer Gene Ther (2004) 0.98
Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival. Pathol Oncol Res (2011) 0.98
Occurence of stromal myofibroblasts in the invasive ductal breast cancer tissue is an unfavourable prognostic factor. Anticancer Res (2007) 0.97
Expression of multidrug resistance-associated protein 1 in invasive ovarian carcinoma: implication for prognosis. Histopathology (2009) 0.97
RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol (2004) 0.96
A Web-based data warehouse on gene expression in human malignant melanoma. J Invest Dermatol (2006) 0.95
Acquired cisplatin resistance in the head-neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1. Int J Cancer (2008) 0.95
CD46 expression is indicative of shorter revival-free survival for ovarian cancer patients. Anticancer Res (2007) 0.94
Study of therapy resistance in cancer cells with functional proteome analysis. Clin Chem Lab Med (2002) 0.94
Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX. Inflamm Res (2009) 0.94
Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA. Mol Ther (2007) 0.91
Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes. Int J Oncol (2007) 0.91
Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome. Virchows Arch (2007) 0.91
Topoisomerase IIalpha mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis. Mod Pathol (2009) 0.90
Influx and efflux transport as determinants of melphalan cytotoxicity: Resistance to melphalan in MDR1 overexpressing tumor cell lines. Biochem Pharmacol (2009) 0.90
Study of the development of chemoresistance in melanoma cell lines using proteome analysis. Electrophoresis (2003) 0.90
CD24 expression is specific for tamoxifen-resistant ductal breast cancer cases. Anticancer Res (2006) 0.89
The gene polymorphism of the angiotensin I-converting enzyme correlates with tumor size and patient survival in colorectal cancer patients. Neoplasia (2007) 0.89
Multidrug-resistant cancer cells facilitate E1-independent adenoviral replication: impact for cancer gene therapy. Cancer Res (2004) 0.89
Elevated nuclear S100P expression is associated with poor survival in early breast cancer patients. Histol Histopathol (2013) 0.89
Complete reversal of ABCG2-depending atypical multidrug resistance by RNA interference in human carcinoma cells. Oligonucleotides (2006) 0.89
ABCC2 (MRP2, cMOAT) localized in the nuclear envelope of breast carcinoma cells correlates with poor clinical outcome. Pathol Oncol Res (2011) 0.88
Identification of differentially expressed genes in classical and atypical multidrug-resistant gastric carcinoma cells. Anticancer Res (2003) 0.87
Comparision of the cytotoxic effects of birch bark extract, betulin and betulinic acid towards human gastric carcinoma and pancreatic carcinoma drug-sensitive and drug-resistant cell lines. Molecules (2009) 0.87
Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP. Mol Ther (2005) 0.87
Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents. Cancer Res (2006) 0.86
Delivery of short hairpin RNAs by transkingdom RNA interference modulates the classical ABCB1-mediated multidrug-resistant phenotype of cancer cells. Cell Cycle (2009) 0.86
Taxol-resistance-associated gene-3 (TRAG-3/CSAG2) expression is predictive for clinical outcome in ovarian carcinoma patients. Virchows Arch (2007) 0.86
Elevated YB-1 expression is a new unfavorable prognostic factor in non-Hodgkin's lymphomas. Anticancer Res (2011) 0.85
Effect of YB-1 on the regulation of micro RNA expression in drug-sensitive and drug-resistant gastric carcinoma cells. Anticancer Res (2010) 0.85
Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients. Anticancer Res (2011) 0.85
Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells. Int J Cancer (2002) 0.84
Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients. Oncol Rep (2007) 0.84
YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells. J Transl Med (2013) 0.84
Transport of phosphatidylserine via MDR1 (multidrug resistance 1)P-glycoprotein in a human gastric carcinoma cell line. Biochem J (2002) 0.84
Elevated nuclear YB1 expression is associated with poor survival of patients with early breast cancer. Anticancer Res (2012) 0.84
Analysis of gene expression profiles in melanoma cells with acquired resistance against antineoplastic drugs. Melanoma Res (2006) 0.82
Regulation of MDR1 gene expression in multidrug-resistant cancer cells is independent from YB-1. Biochem Biophys Res Commun (2007) 0.82
In vitro analysis of the relationships between metallothionein expression and cisplatin sensitivity of non-small cellular lung cancer cells. Anticancer Res (2013) 0.82
Impact of radiation therapy on the oncolytic adenovirus dl520: implications on the treatment of glioblastoma. Radiother Oncol (2007) 0.82
Antineoplastic activity of 2-methoxyestradiol in human pancreatic and gastric cancer cells with different multidrug-resistant phenotypes. J Gastroenterol Hepatol (2007) 0.82
Overcoming multidrug resistance by RNA interference. Methods Mol Biol (2010) 0.82
Decreased expression of p16 in ovarian cancers represents an unfavourable prognostic factor. Histol Histopathol (2008) 0.81
Phenolic compounds as selective antineoplasic agents against multidrug-resistant human cancer cells. Planta Med (2010) 0.81
YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma. Int J Cancer (2011) 0.81
Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2. Cancer Gene Ther (2002) 0.81
Study of the development of thermoresistance in human pancreatic carcinoma cell lines using proteome analysis. Electrophoresis (2004) 0.80
Chromosomal imbalances associated with drug resistance and thermoresistance in human pancreatic carcinoma cells. Eur J Cell Biol (2004) 0.80
A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels. J Cancer Res Clin Oncol (2014) 0.80
Prognostic value of immunohistochemical estimation of CD24 and Ki67 expression in cisplatin and paclitaxel treated ovarian carcinoma patients. Pol J Pathol (2005) 0.80
Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520. Hum Gene Ther (2006) 0.80
Transcriptome analysis of different multidrug-resistant gastric carcinoma cells. In Vivo (2005) 0.80
Novel structure-activity relationships and selectivity profiling of cage dimeric 1,4-dihydropyridines as multidrug resistance (MDR) modulators. Bioorg Med Chem (2010) 0.80
Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers. Cancer Lett (2005) 0.80
PXR and NF-κB correlate with the inducing effects of IL-1β and TNF-α on ABCG2 expression in breast cancer cell lines. Eur J Pharm Sci (2012) 0.79
Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells. Oncogene (2004) 0.79
Positive correlation between cyclooxygenase-2 and ABC-transporter expression in non-Hodgkin's lymphomas. Oncol Rep (2009) 0.79
Positive correlation between cyclooxygenase 2 and the expression of ABC transporters in non-small cell lung cancer. Anticancer Res (2008) 0.78
Impact of novel MDR modulators on human cancer cells: reversal activities and induction studies. Pharm Res (2008) 0.77
Estradiol, tamoxifen and ICI 182,780 alter alpha3 and beta1 integrin expression and laminin-1 adhesion in oral squamous cell carcinoma cell cultures. Oral Oncol (2007) 0.77
Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cells and for ovarian cancer cases of longer survival rates. Int J Gynecol Pathol (2006) 0.77
CD46 Expression is an unfavorable prognostic factor in breast cancer cases. Appl Immunohistochem Mol Morphol (2011) 0.77
Bone physiology in human grafted and non-grafted extraction sockets--an immunohistochemical study. Clin Oral Implants Res (2012) 0.77
Delivery of siRNAs to cancer cells via bacteria. Methods Mol Biol (2015) 0.77
Jet-injection of short hairpin RNA-encoding vectors into tumor cells. Methods Mol Biol (2010) 0.77
Development of small-molecule P-gp inhibitors of the N-benzyl 1,4-dihydropyridine type: novel aspects in SAR and bioanalytical evaluation of multidrug resistance (MDR) reversal properties. Bioorg Med Chem (2012) 0.77
Healing of ungrafted and grafted extraction sockets after 12 weeks: a prospective clinical study. Int J Oral Maxillofac Implants (2011) 0.76
Enhanced immunoreactivity of TIMP-2 in the stromal compartment of tumor as a marker of favorable prognosis in ovarian cancer patients. J Histochem Cytochem (2012) 0.76
Novel insight in structure-activity relationship and bioanalysis of P-glycoprotein targeting highly potent tetrakishydroxymethyl substituted 3,9-diazatetraasteranes. J Med Chem (2008) 0.76
MRP2 (ABCC2, cMOAT) expression in nuclear envelope of primary fallopian tube cancer cells is a new unfavorable prognostic factor. Arch Gynecol Obstet (2012) 0.76
Multidrug resistance reversal properties and cytotoxic evaluation of representatives of a novel class of HIV-1 protease inhibitors. J Pharm Pharmacol (2010) 0.75
Betulinic acid exhibits stronger cytotoxic activity on the normal melanocyte NHEM-neo cell line than on drug-resistant and drug-sensitive MeWo melanoma cell lines. Mol Med Rep (2011) 0.75
Effective knock down of very high ABCG2 expression by a hammerhead ribozyme. Anticancer Res (2004) 0.75
Association of genomic imbalances with drug resistance and thermoresistance in human gastric carcinoma cells. Int J Cancer (2003) 0.75
Influence of tamoxifen on cisplatin-sensitivity and estrogen receptors expression in ovarian carcinoma cell lines. Ginekol Pol (2010) 0.75
Regulation of mRNA expression in drug-sensitive and drug-resistant gastric carcinoma cells is independent of YB-1 expression. Anticancer Res (2010) 0.75
Osteogenic potential of mesenchymal cells embedded in the provisional matrix after a 6-week healing period in augmented and non-augmented extraction sockets: an immunohistochemical prospective pilot study in humans. Clin Oral Implants Res (2011) 0.75